Text Size

An Open-Label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.

This study has been completed.
Sponsor:
Collaborator:
Ortho-McNeil Janssen Scientific Affairs, LLC
Information provided by:
Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00206336
First received: September 13, 2005
Last updated: April 30, 2009
Last verified: April 2009
History of Changes
  Purpose

Previous studies using topiramate in Tourette subjects have shown that with the use of this medication subjects report that their tics get better. The purpose of this study is to study if topiramate improves the symptoms of Tourette syndrome, such as motor tics, or other associated symptoms such as attention or obsessive-compulsive problems.


Condition Intervention Phase
Tourette Syndrome
 Drug: Topiramate (drug)
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome

Resource links provided by NLM:

Drug Information available for: Topiramate
U.S. FDA Resources

Further study details as provided by Baylor College of Medicine:

Study Start Date: October 2004
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   7 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must continue to meet the specific inclusion criteria outlined in either CAPSS-176 or CAPSS-198 to enroll in this protocol.
  • Subjects must have completed the Double-Blind Phase or discontinued the Double-Blind Phase after a minimum of 6 weeks due to lack of efficacy (defined by a CGI improvement score of >6 [much worse or very much worse]) in either CAPSS-176 or CAPSS-198.
  • Subjects or their parents/guardians, must be able to read and comprehend written instructions and willing to complete all scales and assessments required by this protocol.
  • After full explanation of the study, subjects, or their parent/legally authorized representatives, must demonstrate their willingness to participate by signing an informed consent form. If applicable, pediatric subjects capable of giving assent must sign the assent form.
  • Subjects must continue their current treatment for tics, treatment of comorbid symptoms or treatment of A-D/HD at the dose level established prior to entry in the Double-Blind Phase of CAPSS-176 or CAPSS-198.

Exclusion Criteria:

  • Subjects must continue to meet the specific exclusion criteria outlined in either CAPSS-176 or CAPSS-198 to enroll in this protocol.
  • Subjects who have SGOT and/or SGPT levels greater than 2 times the upper limit of the normal range from the last visit in either CAPSS-176 or CAPSS-198 will not be permitted to enroll in the current study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00206336

Sponsors and Collaborators
Baylor College of Medicine
Ortho-McNeil Janssen Scientific Affairs, LLC
Investigators
Principal Investigator: Joseph Jankovic, MD Baylor College of Medicine
  More Information

No publications provided

Responsible Party: Joseph Jankovic, MD, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00206336     History of Changes
Other Study ID Numbers: CAPSS-286
Study First Received: September 13, 2005
Last Updated: April 30, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Tourette Syndrome
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tic Disorders
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mental Disorders Diagnosed in Childhood
 Mental Disorders
Topiramate
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents

ClinicalTrials.gov processed this record on May 16, 2013